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Abstract
MDM2, an E3 ubiquitin ligase, is an important negative regulator of tumor suppressor p53.
In turn theMdm2 gene is a transcriptional target of p53, forming a negative feedback loop
that is important in cell cycle control. It has recently become apparent that the ubiquitination
of p53 by MDM2 can be inhibited when certain ribosomal proteins, including RPL5 and
RPL11, bind to MDM2. This inhibition, and the resulting increase in p53 levels has been pro-
posed to be responsible for the red cell aplasia seen in Diamond-Blackfan anemia (DBA)
and in 5q- myelodysplastic syndrome (MDS). DBA and 5q- MDS are associated with inher-
ited (DBA) or acquired (5q- MDS) haploinsufficiency of ribosomal proteins. A mutation in
Mdm2 causing a C305F amino acid substitution blocks the binding of ribosomal proteins.
Mice harboring this mutation (Mdm2C305F), retain a normal p53 response to DNA damage,
but lack the p53 response to perturbations in ribosome biogenesis. While studying the inter-
action between RP haploinsufficiency and theMdm2C305Fmutation we noticed that
Mdm2C305F homozygous mice had altered hematopoiesis. These mice developed a mild
macrocytic anemia with reticulocytosis. In the bone marrow (BM), these mice showed a sig-
nificant decrease in Ter119hi cells compared to wild type (WT) littermates, while no
decrease in the number of mature erythroid cells (Ter119hiCD71low) was found in the
spleen, which showed compensated bone marrow hematopoiesis. In methylcellulose cul-
tures, BFU-E colonies from the mutant mice were slightly reduced in number and there was
a significant reduction in CFU-E colony numbers in mutant mice compared with WT controls
(p < 0.01). This erythropoietic defect was abrogated by concomitant p53 deficiency
(Trp53ko/ko). Further investigation revealed that inMdm2C305F animals, there was a
decrease in Lin-Sca-1+c-Kit+ (LSK) cells, accompanied by significant decreases in multipo-
tent progenitor (MPP) cells (p < 0.01). Competitive BM repopulation experiments showed
that donor BM harboring theMdm2C305Fmutation possessed decreased repopulation
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capacity compared to WT BM, suggesting a functional stem cell deficit. These results sug-
gest that there is a fine tuned balance in the interaction of ribosomal proteins with the
MDM2/p53 axis which is important in normal hematopoiesis.
Introduction
Diamond-Blackfan Anemia (DBA) is a bone marrow failure syndrome characterized by mac-
rocytic anemia and red cell aplasia, sometimes associated with developmental anomalies,
chiefly cleft palate, thumb abnormalities and cardiovascular problems [1, 2]. Patients are usu-
ally diagnosed in their first year and can be treated with steroids or blood transfusion. In at
least 70% of cases the disease is due to an inherited mutation in one of several ribosomal pro-
teins, though the mechanism whereby haploinsufficiency for ribosomal proteins, which are
required in all dividing cells, leads to specific problems with erythropoeisis, has not been eluci-
dated [3]. In acquired 5q- MDS, patients also have a defect in erythroid cell differentiation with
macrocytic anemia and red cell aplasia [4]. The gene for a ribosomal protein RPS14 is present
in the deleted region and appears to be responsible for the development of the red cell defect
[5]. In animal and cellular models, defects in red cell production caused by ribosomal protein
deficiencies are rescued by the absence of p53, which responds to cellular signals and controls
progression through cell cycle checkpoints [6–9]. p53 is regulated by the E3 ubiquitin ligase
MDM2, which ubiquitinates p53 stimulating its turnover within the nucleus [10–15]. The
Mdm2 gene is a transcriptional target of p53 thus forming a feedback loop that controls p53
and MDM2 levels [16]. Certain ribosomal proteins, notably RPL5 and RPL11, bind to MDM2
and block its ability to inhibit p53. This mechanism was demonstrated by the inability of ribo-
some biogenesis to affect p53 in cells homozygous for a mutant MDM2 with a C305F mutation,
which fails to bind these ribosomal proteins (RPs) [17]. Cells homozygous forMdm2C305F have
a normal p53 response to DNA damage but not to ribosomal stress.
A crucial stage in mammalian erythropoiesis takes place in erythroblasts, rapidly proliferat-
ing cells with a maximum rate of ribosome production, needed for globin synthesis. The co-
ordination between ribosome synthesis and cell division must be closely regulated in these
cells, given the abortive effects on erythropoiesis when ribosome synthesis is perturbed. We
therefore hypothesized that the RP/MDM2/p53 axis may play a crucial role in normal erythro-
poiesis. To test our hypothesis we studied erythropoiesis in homozygousMdm2C305F mice
compared to wild type (WT) mice. We found thatMdm2C305F mice had distinct abnormalities
in erythropoiesis that point to the importance of RP/MDM2 binding in regulating red cell
production.
Materials and Methods
Mdm2mutant mice and animal experiments
We obtained mice carryingMdm2C305F mutation from Dr. Zhang [18], and Trp53ko (129S2/
SvPas) from the Jackson Laboratory. Animals were interbred to maintainMdm2C305F, which
was bred to C57BL/6 mice for studies. All mice were handled in strict accordance with our pro-
tocol (IACUC 911) as approved by the institutional animal care and use committee at the Chil-
dren’s Hospital of Philadelphia Animal Care Facility.
Peripheral Blood cell counts were performed using a Hemavet HV950FS analyzer (Drew
Scientific). Absolute reticulocyte counts and erythrocyte adenosine deaminase (eADA) were
performed as previously described [19, 20]. For erythropoietin, lactate dehydrogenase (LDH),
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and bilirubin serum levels, serum from the mice was collected by centrifugation of whole
peripheral blood at 1,000 g for 20 minutes. Erythropoietin levels in serum were determined by
ELISA assay kit (R&D Systems) [21]. LDH and bilirubin in serum were analyzed used a Vistros
350 chemistry system (Ortho Clinical).
Histology and immunohistochemistry
Mouse peripheral blood smears were stained with May-Grunwald (Sigma-Aldrich) and Gimsa
(Sigma-Aldrich) reagents. Mouse bone marrow and spleen tissue were fixed in 10% formalin.
Bones were decalcified before dehydration, paraffin-embedded, and cut into 5 μm sections. For
immunohistochemistry, Ter119 antibody (BD Biosciences) was used to stain formalin fixed
paraffin embedded TMA slides. The sections were then incubated with TER-119 antibody at a
1:50 dilution for 1 hour at room temperature and then were incubated with biotinylated anti-
rat IgG (Vector Laboratories) for 30 min at room temperature. After rinsing, sections were
then incubated with the avidin biotin complex (Vector Laboratories) for 30 min at room temp.
The sections were then rinsed and incubated with DAB (DAKO Cytomation) for 10 min at
room temperature. The sections were also counterstained with hematoxylin and eosin (Sigma-
Aldrich), rinsed, dehydrated in ethanol followed by xylene, then coverslipped. The prepara-
tions were examined by light microscopy (BX43; Olympus).
Flow cytometric measurements
For assessment of bone marrow and spleen progenitor cells by flow cytometry, single-cell
suspensions of freshly prepared bone marrow and spleen were incubated with the following
anti-mouse monoclonal antibodies: Ter119 (Ly-76, BD Biosciences), CD71 (C2, BD Biosci-
ences), CD34 (RAM34, BD Biosciences), CD135 (A2F10, eBioscience), CD127 (A7R34,
eBioscience), c-Kit (ACK2, eBioscience), SCA-1 (LY-6A/E, BD Biosciences), eFluor520
(eBioscience), and 7-AAD (eBioscience). Lineage (lin) staining included anti-mouse Ter119
(BD Biosciences), GR-1 (RB6-8C5, BD Biosciences), B220 (RA3-6B2, BD Biosciences), CD4
(RM4-5, BD Biosciences), CD8 (53–6.7, BD Biosciences), and CD11b (M1/70, BD Biosci-
ences) antibodies [22–24]. Multicolor data acquisition for bone marrow progenitor subsets
was performed on a FACSCanto II flow cytometer, and data were analyzed with FlowJo
7.6.1.
Colony-forming cell assays
Bone marrow (BM) cells were plated in triplicate in Methocult M3334 (StemCell Technologies)
into 35 mm dishes at the density of 2 x 105 cells per dish and cultured for 2 days (CFU-E) or 4
days (mature BFU-E). BM cells were plated in triplicate in Methocult M3434 (StemCell Tech-
nologies) into 35 mm dishes at the density of 2 x 105 or 2 x 104 cells per dish and cultured for 7
days (BFU-E and CFU-GEMM) or 12 days (CFU-GM) [25]. Cells were stained with Benzidine
dihydrochloride (Sigma-Aldrich) solution and visible colonies were counted.
Bone marrow transplantation and long-term repopulating assay
Competitive repopulation assays were performed by injecting 2.5×106 bone marrow cells from
either experimental (Mdm2C305F/C305F) or control (Mdm2C305F/+, C57BL/6) donor animals on a
CD45.2 background, along with 2.5×106 competitor cells from CD45.1 C57BL/6 mice into irra-
diated (900 cGy) C57BL/6 recipient mice (CD45.1) [26, 27]. Peripheral blood samples were col-
lected at 4, 8, and 12 weeks following transplant to assess for the percentage of reconstitution
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of peripheral blood cell lineages with CD45.2 cells, thus defining relative repopulation capacity
of bone marrow harvested from our experimental versus control mouse strains in each lineage
analyzed. Leukocyte subsets were assessed after RBC lysis with ammonium chloride, using the
following antibodies: FITC antibodies against, B220 (RA3-6B2, BD Biosciences), TCR β (H57-
597, BD Biosciences), CD45.2 (104, BD Biosciences), and CD4 (GK1.5, BD Biosciences); PE
antibodies against, CD11b (M1⁄70, BD Biosciences), Gr-1 (RB6-8C5, BD Biosciences), CD8
(53–6.7, eBioscience), and CD45.1 (A20, BD Biosciences).
Statistical analysis
Data were analyzed for statistical significance with the 2-tailed paired Student’s t-test
(p< 0.05;P< 0.01, Excel 2013, Microsoft Corporation) for 2-group comparisons. Error
bars were generated using the standard error of the mean.
Results
Hematologic characterization inMdm2C305F/C305Fmutant mice
To examine our hypothesis that co-ordination of ribosome biogenesis and the cell cycle is
important in hematopoiesis we first studied peripheral blood counts in mice homozygous for
Mdm2C305F/C305F. These mice displayed a mild macrocytic anemia with reticulocytosis
(Table 1). Red cell morphology, other than a mild macrocytosis, was normal and there were no
signs of hemolysis. Erythropoietin levels were higher in mutant mice compared to wild type,
but this did not reach statistical significance (p = 0.118). eADA levels, known to be increased in
red blood cells from patients with DBA due to ribosomal protein gene mutations, were normal
in red blood cells fromMdm2C305F/C305F mutant mice. White blood cells and platelets were not
significantly different between mutant and control mice. The anemia correlated with
Mdm2C305F gene dosage with the homozygous mice exhibiting lower levels of hemoglobin and
number of red blood cells than the heterozygous mice.
We also found that homozygous mutantMdm2C305F animals had a decreased number of
nucleated cells in bone marrow and splenomegaly compared to control animals (Table 1).
Mdm2C305F homozygous and heterozygous mice were indistinguishable from wild type mice
with no noticeable differences in appearance and body weight. Animals were healthy and dur-
ing the observation period of 12 months no tumors were observed in mutant or wild type mice.
The cellular makeup ofMdm2C305F homozygous spleens was determined by comparative
histology and immunophenotyping using flow cytometry. Germinal centers were histologically
normal, but the red pulp was increased (Fig 1), with increased staining for glycophorin-associ-
ated Ter119, a marker of erythroid cells.
In the bone marrowMdm2C305F homozygous mice showed a significant decrease in Ter119-
high cells compared to wild type littermates as measured by flow cytometry. In contrast, while
the spleen contained a decreased percentage of Ter119high cells, the total number of mature ery-
throid cells (Ter119hiCD71low) in the spleen was not decreased. This discrepancy between ery-
throid cell percentage and absolute number in the spleen was due to the splenomegaly and
expanded red pulp seen inMdm2C305F homozygous mice, which is consistent with compensa-
tory increased extramedullar (splenic) erythropoiesis in these mice (Fig 2).
In methyl cellulose cultures BFU-E colonies from the mutant mice were slightly reduced in
number and there was an even greater reduction in CFU-E colony numbers in mutant mice
compared with WT controls (p< 0.001) (Fig 3). CFU-GEMM and CFU-GM were not signifi-
cantly different between mutant and control mice (Fig 3).
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Mdm2C305F/C305Fmutant mice are defective in stem cell renewal
To explore the ontogeny of the erythroid defects caused by theMdm2C305F mutation in the
mouse, we analyzed specific precursor populations in the bone marrow cells.Mdm2C305F
mutant animals exhibited a significant decrease in Lin-Sca-1+c-Kit+ (LSK) cells, accompanied
by significant decreases in multipotent progenitor (MPP) cells (p< 0.01) (Fig 4).
Next, we were interested in whether the abnormality inMdm2C305F mutant occurs during
hematopoietic differentiation or also at the stem cell level. For this, competitive BM transplant
experiments were performed using a 50:50 mixture of BM cells from eitherMdm2C305F homo-
zygous or heterozygous mutant mice and WTmice all at 8 weeks of age. After primary trans-
plantation BM cells fromMdm2C305F homozygous mice contributed only little to circulating B
and T lymphocytes compared to WT derived BM cells, whereas the contribution to the myeloid
Table 1. Effects ofMdm2C305Fmutant on blood counts, lactate dehydrogenase, bilirubin, erythropoietein level, and eADA activity.
C57BL/6 Mdm2C305F/+ Mdm2C305F/C305F Mdm2C305F/C305F;Trp53ko/ko
No. of animals 13 12 12 14
WBC(x103/μL) 7.19 ± 2.30 6.73 ± 1.54 6.27 ± 1.91 7.46 ± 1.65
Neutrophil(x103/μL) 0.69 ±0.28 0.89 ± 0.42 0.78 ± 0.24 1.51 ± 0.34 a§
Lymphocyte(x103/μL) 6.94 ± 1.96 5.60 ± 1.33 5.26 ± 1.65 5.70 ± 1.43
Monocyte(x103/μL) 0.27 ± 0.12 0.23 ± 0.07 0.20 ± 0.06 0.23 ± 0.09
Eosinophil(x103/μL) 0.02 ± 0.02 0.02 ± 0.01 0.03 ± 0.02 0.01 ± 0.01 c§
Basophil(x103/μL) 0.00 ± 0.01 0.01 ± 0.01 0.00 ± 0.01 0.00 ± 0.01
RBC(x106/μL) 11.45 ± 0.59 10.68 ± 0.93 9.87 ± 1.03 a† 10.05 ± 0.50
Hb(g/dL) 14.74 ± 0.75 13.58 ± 1.00 13.53 ± 1.19 b† 13.10 ± 0.79
MCV(fL) 51.89 ± 4.05 54.83 ± 4.14 58.88 ± 3.79 a† 52.66 ± 0.94 a§
Reticulocyte(‰) 3.09 ± 0.81 4.05 ± 0.93 4.64 ± 1.29 b† 4.89 ± 0.94
Platelets(x103/μL) 729.54 ± 113.81 722.08 ± 134.73 695.50 ± 86.27 812.00 ± 80.29 c§
No. of animals 7 7 6 4
LDH(IU/L) 522.71 ± 60.2 505.00 ± 53.42 565.67 ± 95.28 617.8 ± 159.01
T-Bil(mg/dL) 0.39 ± 0.12 0.39 ± 0.14 0.43 ± 0.05 0.40 ± 0.12
No. of animals 17 12 13 15
Epo(pg/ml) 168.73 ± 46.60 169.07 ± 44.40 204.93 ± 71.78 168.71 ± 66.43
No. of animals 9 8 12 5
eADA(IU/g Hb) 1.15 ± 0.18 1.16 ± 0.16 1.16 ± 0.22 1.11 ± 0.16
No. of animals 15 8 8 9
Body weight(g) 27.60 ± 4.48 29.27 ± 3.10 26.27 ± 3.48 29.17 ± 4.21
No. of animals 15 8 8 13
Bone marrow cells(x107 cells) 4.534 ± 0.561 4.337 ± 0.870 3.609 ± 0.770 b† 3.925 ± 0.591
No. of animals 21 9 9 12
Spleen(mg) 79.5 ± 13.2 84.1 ± 14.2 100.3 ± 15.2 b† 107.0 ± 29.3
Blood counts analyses of mice at 6 weeks of age. Bone marrow cellularity determined by flushing 2 femurs and 2 tibias. WBC indicates white blood cell
count; RBC, red blood cell count; Hb, hemoglobin; MCV, mean corpuscular volume; LDH, lactate dehydrogenase; T-bil, total bilirubin; Epo, erythropoietin;




† C57BL/6 vs Mdm2C305F/C305F
§ Mdm2C305F/C305F vs Mdm2C305F/C305F;Trp53
doi:10.1371/journal.pone.0152263.t001
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lineage in peripheral blood at day 28 after transplant was approximately equal to WT competi-
tor cells but decreased with time after transplant (S1 Fig). In contrast, forMdm2C305F heterozy-
gous and WT BM cells the contribution was higher and remained stable during the
observation period suggesting, a defect at an earlier precursor, possibly at a stem cell level.
The results from competitive BM transplant experiments indicate thatMdm2C305F homozy-
gous BM cells have an intrinsic proliferative defect at an early progenitor level as well and pos-
sibly more pronounced during erythroid differentiation compared toMdm2C305F heterozygous
or WT mice.
Effects ofMdm2C305F/C305F are partially corrected by Trp53ko/ko
We next asked whether p53 was required for the observed hematologic changes in the
Mdm2C305Fmutant mouse. For thisMdm2C305F animals were crossbred with mice carrying a
p53 knockout allele, to generate mice homozygous forMdm2C305F and Trp53ko. InMdm2C305F
animals, deficiency for p53 (Trp53ko/ko) mitigated the increase in mean corpuscular volume
(MCV) at 6 weeks of age, although the RBC count and Hemoglobin did not significantly increase
and reticulocytosis persisted (Table 1). Double homozygousMdm2C305F/C305F;Trp53ko/komice
had a persistent splenomegaly with a significant increase in basophilic and chromatophilic
erythroblasts (Fig 2). Furthermore, BFU-E's, CFU-E's, CFU-GEMM's, andMPP's from the
Mdm2C305F/C305F;Trp53ko/komice were significantly increased in number compared to
Mdm2C305Fmutant mice (Figs 3 and 4). This suggests that the loss of p53 rescues impaired
mutantMdm2C305F erythropoiesis at least in part.Mdm2C305F/C305F;Trp53ko/komice showed also
a significant increase in the number of neutrophil and platelets, however this was not different to
the neutrophil and plated counts in p53 mutant mice thus likely caused by the p53 knockout
background [28].
Fig 1. Effects ofMdm2C305Fmutant on peripheral blood, bonemarrow, and spleen histology. (A) Hematoxylin and eosin stained splenic sections
(Magnification: 40x). (B) Ter119-stained (brown) splenic sections. Blue is counterstained lymphoid tissue.
doi:10.1371/journal.pone.0152263.g001
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Fig 2. Effects ofMdm2C305Fmutant on erythroid maturation in bonemarrow and spleen. Flow
cytometric assessment of cell-surface Ter119 and CD71 expression in bone marrow and spleen, used to
define population of proerythroblasts (I; Ter119medCD71hi), basophilic erythroblasts (II; Ter119hiCD71hi),
chromatophilic erythroblasts (III; Ter119hiCD71med), and orthochromatic erythroblasts (IV; Ter119hiCD71low).
Specific populations in control (n = 25),Mdm2C305F heterozygous (n = 9),Mdm2C305F homozygous (n = 8),
andMdm2C305F/C305F;Trp53ko/komice (n = 8). (A) Representative flow cytometry analysis of bone marrow.
(B)Mdm2C305F homozygous mice showed a significant decrease in Ter119high cells compared to wild type
littermates in the bone marrow. (C) Representative flow cytometry analysis of spleen. (D)Mdm2C305F
homozygous mice showed no decrease in the number of mature erythroid cells (Ter119hiCD71low) compared
to wild type littermates in the spleen.
doi:10.1371/journal.pone.0152263.g002
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Discussion
DBA and 5q- MDS are associated with inherited and acquired haploinsufficiency of ribosomal
proteins. Recent studies have implicated the role of p53 in mediating a cellular response to
abnormal ribosome biogenesis and a ribosome deficient animal model showed p53-dependent
abnormalities in development and hematopoiesis [29].
Fig 3. Hematopoietic colony assays inMdm2C305Fmutant mice.Hematopoietic colony assays in C57BL/6 (n = 14),Mdm2C305F heterozygous (n = 7),
Mdm2C305F homozygous (n = 7), andMdm2C305F/C305F;Trp53ko/ko (n = 7) mice. Mean ± standard error of mean, two-tailed Student’s t-test (*P < 0.05,
**P < 0.01). BFU-E colonies from the mutant mice were slightly reduced in number and there was a significant reduction in CFU-E colony numbers in mutant
mice compared with wild type (WT) controls.
doi:10.1371/journal.pone.0152263.g003
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Fig 4. Effects ofMdm2C305Fmutant on selected hematopoietic lineage subpopulation in bonemarrow. (A) Representative flow cytometry analysis of
the specific precursor populations in control (n = 7),Mdm2C305F homozygous (n = 6), andMdm2C305F/C305F;Trp53ko/komice (n = 6). (B)Mdm2C305Fmutant
animals exhibited a significant paucity in the HSPC population of LSKs (P < 0.01), accompanied by significant decreases of MPP populations (P < 0.01).
HSPC indicates hematopoietic stem and progenitor cell; LSK, Lin-Sca-1+c-Kit+; LT-HSC, long-term hematopoietic stem cells; ST-HSC, short-term
hematopoietic stem cells; MPP, multipotent progenitor; CLP, common lymphoid progenitor; and CMP, commonmyeloid progenitor.
doi:10.1371/journal.pone.0152263.g004
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Fig 5. Diagram of the hematopoietic lineage and differences observed inMdm2C305Fmutant mice. (A)Mdm2C305F phenotype corresponded to blocks
at MPP and orthochromatic erythroblast. LSK indicates Lin-Sca-1+c-Kit+; LT-HSC, long-term hematopoietic stem cells; ST-HSC, short-term hematopoietic
stem cells; MPP, multipotent progenitor; CLP, common lymphoid progenitor; CMP, commonmyeloid progenitor; GMP, granulocyte/macrophage progenitor;
PreMegE, megakaryocyte–erythroid progenitor; and MKP, megakaryocyte progenitor. (B) RP/MDM2 interaction may be important for the mature
hematopoiesis rather than for the HSC proliferation.
doi:10.1371/journal.pone.0152263.g005
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Oncogene-induced p53 activation is a major tumor-suppressor mechanism [10–12].
MDM2 is an important negative regulator of p53 that is important in cell cycle control. Recent
study has demonstrated thatMdm2C305F mutation disrupted ribosomal protein binding and
exhibited a normal p53 response to DNA damage but failed to activate p53 after perturbations
in ribosome biogenesis [17].
While studying the interaction between RP haploinsufficiency, we noticed thatMdm2C305F
mutant mice themselves had perturbed hematopoiesis. These mice showed a dramatic decrease
in progenitor cells and a delayed erythroid differentiation without obvious myeloid and lym-
phoid lineages defects (Fig 5), a phenotype reminiscent to the defect described in CD34+ cells
from DBA patients with inherited RPL11mutations, underlining the importance of the co-
ordination of ribosome biogenesis with cell cycle control in erythropoiesis[30].
Similar to the experiments using RPL11 deficient human CD34+ cells from patients with
DBA, p53 knockout in ourMdm2mutant animals partially mitigated the decrease in progeni-
tor cells and the delayed hematopoiesis in our mice. However, although the progenitor num-
bers fromMdm2C305F mutant mice were mitigated by p53 knockout the animals were still
anemic although they lost theMdm2C305F associated macrocytosis, suggesting that the half-life
of the matureMdm2C305F p53mutant red cells is decreased. Indeed double mutantMdm2C305F
p53 knockout mice had slightly elevated LDH levels and the accumulation of iron in their
spleen (Table 1, S2 Fig).
Previous studies showed that MDM2 deficiency in mice results in embryonic lethality due
to massive apoptosis and this phenotype was rescued by the p53515C allele, which encodes an
apoptosis-deficient protein [16]. These mice died early, due to a severe impairment of pro-
genitor cell expansion during postnatal hematopoiesis, leading to p53-dependent cell cycle
arrest. These results show the regulation of p53 by MDM2 is important in hematopoiesis. In
contrast to these studies, ourMdm2C305F mutant mice show similar survival to wild type
[17].
Very recently the RPS19-deficient DBA withMdm2C305F knock-in mice were published
[31]. Mdm2C305F improved expansion of hematopoietic progenitors, but the extent of the ery-
throid rescue by Mdm2C305F was only partial, and the selective erythroid defect caused by
Mdm2C305F.
Taken together, our findings with theMdm2C305F knock in mice provide in vivo evidence
that there is a delicate balance between ribosomal proteins and MDM2 binding and the stabili-
zation of p53 as both increased RPL11 binding as well as the inability to bind MDM2 leads to
p53 stabilization, a decreased number of progenitor cells and defective erythroid maturation.
Supporting Information
S1 Fig. The competitive repopulation ability ofMdm2C305Fmutant bone marrow. The per-
centage of total cell counts derived from donor mice is plotted for granulocytes and monocytes
(Gr-1 and CD11b), B lymphocytes (B220), T lymphocytes (TCR β), CD4+ lymphocytes (CD4),
CD8+ lymphocytes (CD8), and from peripheral blood of irradiated recipients 4, 8, or 12 weeks
after BM transplantation with 5 x 106 Mdm2C305Fmutant Bone marrow cells (CD45.2) mixed
with CD45.1 allotype-marked wild type (WT) cells in 1:1 ratio. Donor ages are 6 weeks. n = 3–4
animals per genotype.
(TIF)
S2 Fig. Effects ofMdm2C305Fmutant on spleen histology. Prussian blue stained splenic sec-
tions (Magnification: 400x).
(TIF)
MDM2/Ribosomal Protein and Erythropoiesis
PLOS ONE | DOI:10.1371/journal.pone.0152263 April 4, 2016 11 / 13
Acknowledgments
We thank Patricia Marko and Peter Nicholas for care of mice; Daniel Martines for histology
and immunohistochemistry at the pathology core laboratory.
Author Contributions
Conceived and designed the experiments: TK BG TSO YZ PJMMB. Performed the experi-
ments: TK BG TSO YZ PJMMB. Analyzed the data: TK BG TSO YZ PJMMB. Contributed
reagents/materials/analysis tools: TK BG TSO YZ PJMMB. Wrote the paper: TK BG TSO YZ
PJMMB.
References
1. Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, et al. Diagnosing and treating Diamond
Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008; 142
(6):859–76. doi: 10.1111/j.1365-2141.2008.07269.x PMID: 18671700; PubMed Central PMCID:
PMC2654478.
2. Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis.
Hematol Oncol Clin North Am. 2009; 23(2):261–82. doi: 10.1016/j.hoc.2009.01.004 PMID: 19327583;
PubMed Central PMCID: PMC2886591.
3. Farrar JE, Vlachos A, Atsidaftos E, Carlson-Donohoe H, Markello TC, Arceci RJ, et al. Ribosomal pro-
tein gene deletions in Diamond-Blackfan anemia. Blood. 2011; 118(26):6943–51. doi: 10.1182/blood-
2011-08-375170 PMID: 22045982; PubMed Central PMCID: PMC3245214.
4. Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best practice & research
Clinical haematology. 2001; 14(3):479–95. doi: 10.1053/beha.2001.0151 PMID: 11640866.
5. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syn-
drome gene by RNA interference screen. Nature. 2008; 451(7176):335–9. doi: 10.1038/nature06494
PMID: 18202658; PubMed Central PMCID: PMC3771855.
6. McGowan KA, PangWW, Bhardwaj R, Perez MG, Pluvinage JV, Glader BE, et al. Reduced ribosomal
protein gene dosage and p53 activation in low-risk myelodysplastic syndrome. Blood. 2011; 118
(13):3622–33. doi: 10.1182/blood-2010-11-318584 PMID: 21788341; PubMed Central PMCID:
PMC3186336.
7. LohrumMA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the
ribosomal protein L11. Cancer cell. 2003; 3(6):577–87. PMID: 12842086.
8. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, et al. Ribosomal protein L11 negatively regu-
lates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Molec-
ular and cellular biology. 2003; 23(23):8902–12. PMID: 14612427; PubMed Central PMCID:
PMC262682.
9. Bhat KP, Itahana K, Jin A, Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibi-
tion-induced p53 activation. The EMBO journal. 2004; 23(12):2402–12. doi: 10.1038/sj.emboj.7600247
PMID: 15152193; PubMed Central PMCID: PMC423289.
10. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323–31. PMID:
9039259.
11. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810):307–10. doi: 10.
1038/35042675 PMID: 11099028.
12. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001; 114(Pt 23):4139–40. PMID: 11739646.
13. Dey A, Lane DP, Verma CS. Modulating the p53 pathway. Seminars in cancer biology. 2010; 20(1):3–
9. doi: 10.1016/j.semcancer.2010.02.004 PMID: 20193765.
14. Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harbor per-
spectives in biology. 2010; 2(12):a000893. doi: 10.1101/cshperspect.a000893 PMID: 20463001;
PubMed Central PMCID: PMC2982174.
15. Bond GL, HuW, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr
Cancer Drug Targets. 2005; 5(1):3–8. PMID: 15720184.
16. Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, Box NF, et al. The p53-Mdm2 network in progenitor
cell expansion during mouse postnatal development. The Journal of pathology. 2007; 213(4):360–8.
doi: 10.1002/path.2238 PMID: 17893884.
MDM2/Ribosomal Protein and Erythropoiesis
PLOS ONE | DOI:10.1371/journal.pone.0152263 April 4, 2016 12 / 13
17. Macias E, Jin A, Deisenroth C, Bhat K, Mao H, LindstromMS, et al. An ARF-independent c-MYC-acti-
vated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer cell. 2010;
18(3):231–43. doi: 10.1016/j.ccr.2010.08.007 PMID: 20832751.
18. LindstromMS, Jin A, Deisenroth C, White Wolf G, Zhang Y. Cancer-associated mutations in the MDM2
zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Molecular and cellular biology. 2007; 27(3):1056–68. doi: 10.1128/MCB.01307-06 PMID: 17116689;
PubMed Central PMCID: PMC1800693.
19. Chin-Yee I, Keeney M, Lohmann RC. Flow cytometric reticulocyte analysis using thiazole orange; clini-
cal experience and technical limitations. Clin Lab Haematol. 1991; 13(2):177–88. PMID: 1718653.
20. Glader BE, Backer K, Diamond LK. Elevated erythrocyte adenosine deaminase activity in congenital
hypoplastic anemia. N Engl J Med. 1983; 309(24):1486–90. doi: 10.1056/NEJM198312153092404
PMID: 6646173.
21. Ikeda K, Mason PJ, Bessler M. 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by con-
ferring a clonal growth advantage at the level of HSC in mice. Blood. 2011; 117(22):5860–9. doi: 10.
1182/blood-2011-02-334425 PMID: 21460244; PubMed Central PMCID: PMC3112035.
22. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T. In vivo and in vitro stem cell func-
tion of c-kit- and Sca-1-positive murine hematopoietic cells. Blood. 1992; 80(12):3044–50. PMID:
1281687.
23. Keel SB, Doty RT, Yang Z, Quigley JG, Chen J, Knoblaugh S, et al. A heme export protein is required
for red blood cell differentiation and iron homeostasis. Science. 2008; 319(5864):825–8. doi: 10.1126/
science.1151133 PMID: 18258918.
24. Olson TS, Caselli A, Otsuru S, Hofmann TJ, Williams R, Paolucci P, et al. Megakaryocytes promote
murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning.
Blood. 2013; 121(26):5238–49. doi: 10.1182/blood-2012-10-463414 PMID: 23667055; PubMed Cen-
tral PMCID: PMC3695366.
25. Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribo-
somal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood.
2011; 117(9):2567–76. doi: 10.1182/blood-2010-07-295238 PMID: 21068437; PubMed Central
PMCID: PMC3062351.
26. Szilvassy SJ, Humphries RK, Lansdorp PM, Eaves AC, Eaves CJ. Quantitative assay for totipotent
reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proceedings of the
National Academy of Sciences of the United States of America. 1990; 87(22):8736–40. PMID:
2247442; PubMed Central PMCID: PMC55034.
27. Jaako P, Flygare J, Olsson K, Quere R, Ehinger M, Henson A, et al. Mice with ribosomal protein S19
deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia.
Blood. 2011; 118(23):6087–96. doi: 10.1182/blood-2011-08-371963 PMID: 21989989.
28. TeKippe M, Harrison DE, Chen J. Expansion of hematopoietic stem cell phenotype and activity in
Trp53-null mice. Experimental hematology. 2003; 31(6):521–7. PMID: 12829028.
29. Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmen-
tal abnormalities and defective erythropoiesis through activation of p53 protein family. Blood. 2008; 112
(13):5228–37. doi: 10.1182/blood-2008-01-132290 PMID: 18515656.
30. Moniz H, Gastou M, Leblanc T, Hurtaud C, Cretien A, Lecluse Y, et al. Primary hematopoietic cells from
DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro.
Cell Death Dis. 2012; 3:e356. doi: 10.1038/cddis.2012.88 PMID: 22833095; PubMed Central PMCID:
PMC3406587.
31. Jaako P, Debnath S, Olsson K, Zhang Y, Flygare J, LindstromMS, et al. Disruption of the 5S RNP-
Mdm2 interaction significantly improves the erythroid defect in a mouse model for Diamond-Blackfan
anemia. Leukemia. 2015. doi: 10.1038/leu.2015.128 PMID: 25987256.
MDM2/Ribosomal Protein and Erythropoiesis
PLOS ONE | DOI:10.1371/journal.pone.0152263 April 4, 2016 13 / 13
